Bristol-Myers Squibb shows growth despite hedge fund selling

Bristol-Myers Squibb has demonstrated significant stock growth, outperforming the S&P 500 by approximately 35% during a period when the index saw a 12% loss. This performance occurred despite hedge funds reducing their aggregate 13F shares by roughly 1.8% in the third quarter of 2022.

Analysts have provided positive earnings and revenue estimates for the company. Projections suggest earnings per share could rise to $7.95 by December 2023, with revenue expected to increase to approximately $47.1 billion.

In recent strategic developments, the biopharmaceutical company secured expanded FDA regulatory approvals for cardiovascular treatments and entered a partnership with Nvidia to utilize artificial intelligence for drug discovery. The company maintains a primary focus on oncology, cardiovascular health, immunology, and fibrotic therapeutic projects.